| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Rhotekin-2, Pleckstrin homology domain-containing family K member 1, PH domain-containing family K member 1, RTKN2, PLEKHK1 |
| Entrez GeneID | 219790 |
| WB Predicted band size | 69.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This RTKN2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 99-127 amino acids from the N-terminal region of human RTKN2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于RTKN2 (N-term)抗体的示例参考文献(注：以下为假设性示例，实际文献请通过学术数据库查询)：
---
1. **文献名称**: *"RTKN2 promotes colorectal cancer progression via Wnt/β-catenin signaling"*
**作者**: Zhang, Y. et al.
**摘要**: 研究通过构建针对RTKN2 N端的特异性抗体，发现RTKN2在结直肠癌组织中高表达，并通过激活Wnt/β-catenin通路促进肿瘤细胞增殖和迁移。
2. **文献名称**: *"Development and validation of a novel anti-RTKN2 antibody for gastric cancer diagnostics"*
**作者**: Li, X. et al.
**摘要**: 报道了一种针对RTKN2 N端的单克隆抗体的开发，验证其在胃癌组织中的特异性结合能力，并证实RTKN2高表达与患者预后不良相关。
3. **文献名称**: *"RTKN2 regulates cytoskeletal dynamics through RhoA interaction in breast cancer"*
**作者**: Wang, H. et al.
**摘要**: 利用RTKN2 N端抗体进行免疫共沉淀实验，揭示RTKN2通过N端结构域与RhoA蛋白互作，调控乳腺癌细胞骨架重组和侵袭能力。
4. **文献名称**: *"Subcellular localization of RTKN2 isoforms in neuronal cells"*
**作者**: Chen, L. et al.
**摘要**: 研究通过N端特异性抗体进行免疫荧光分析，发现RTKN2在神经元细胞中主要定位于细胞质，并参与轴突导向的分子机制。
---
如需具体文献，建议在PubMed或Google Scholar中检索关键词“RTKN2 antibody N-terminal”或联系相关领域的研究团队获取数据。
The RTKN2 (N-term) antibody is designed to target the N-terminal region of Rhotekin 2 (RTKN2), a protein implicated in regulating cytoskeletal dynamics and cellular signaling. RTKN2 belongs to the rhotekin family, which interacts with Rho GTPases, particularly RhoA, to modulate actin organization, cell motility, and polarity. Unlike its homolog RTKN (Rhotekin 1), RTKN2 exhibits distinct expression patterns, with higher levels observed in immune cells and certain cancers, suggesting roles in proliferation, apoptosis, and cancer progression. Studies link RTKN2 overexpression to malignancies like bladder cancer and leukemia, where it may promote tumorigenesis by enhancing cell survival or evading immune surveillance.
The N-terminal-specific antibody enables detection of full-length RTKN2 or its cleavage products in applications such as Western blotting, immunofluorescence, or immunohistochemistry. Its specificity for the N-terminal domain helps distinguish RTKN2 from other family members or splice variants. Researchers use this tool to explore RTKN2's involvement in Rho-mediated pathways, its interplay with cytoskeletal regulators, or its diagnostic/prognostic potential in disease. Validation typically includes testing in knockout models or siRNA-treated cells to confirm signal specificity. As RTKN2's functional diversity remains understudied, this antibody supports ongoing efforts to decode its physiological and pathological roles.
×
